Latest Breaking News On - Pharmacovigilance department - Page 4 : comparemela.com

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in the United States by its partner, global biotechnology leader CSL .

United kingdomNoord hollandUnited statesMatt kapustaEuropean unionBehring pharmacovigilance departmentEuropean economic areaSafety informationPharmacovigilance department

Daiichi Sankyo : Announces Appointments of Directors and Audit & Supervisory Board Members(265 9KB

Press Release Daiichi Sankyo Announces Appointments of Directors and Audit & Supervisory Board Members Tokyo, Japan - - Daiichi Sankyo. | May 16, 2023

Noritaka ujiKazuaki kamaShoji hirashimaTakaaki nishiiMasako watanabeYukiko imazuMitsuhiro matsumotoRyoichi watanabeKenji satoHiroyuki okuzawaYasuhiro komatsuSunao manabeMiyuki araiSawako noharaAlimentos ltdaMasahiko ohtsuki

uniQure (QURE) Reports Publication of HOPE-B Trial Data

uniQure (QURE) Reports Publication of HOPE-B Trial Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChiara russoRicardo dolmetschMariae cantorTom maloneSqure incEuropean commissionDrug administrationLaurencea boxer research professor of pediatricsUniversity of michiganAmerican society of hematologyEuropean unionEuropean association for haemophiliaBehring pharmacovigilance departmentWall streetNew england journal

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandChiara russoRicardo dolmetschMariae cantorTom maloneSqure incEuropean commissionDrug administrationLaurencea boxer research professor of pediatricsUniversity of michiganAmerican society of hematologyEuropean unionEuropean association for haemophiliaBehring pharmacovigilance departmentEuropean economic area

uniQure Inc : uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic

United statesNoord hollandDennis riedlChiara russoRicardo dolmetschMariae cantorTom maloneEuropean commissionDrug administrationLaurencea boxer research professor of pediatricsUniversity of michiganAmerican society of hematologyEuropean unionEuropean association for haemophiliaBehring pharmacovigilance departmentEuropean economic area